BOTTOM LINE WHICH WORKS BETTER?
| Feature / Study Outcome | Wharton’s Jelly MSCs (WJ-MSC) | Adipose-Derived MSCs (AD-MSC) |
|---|---|---|
| Source | Umbilical cord tissue | Patient’s own fat tissue |
| Route of Delivery | Mostly intravenous, some intrabronchial | Mostly intravenous, some intratracheal |
| Preclinical Benefit (Animal Models) | Strong improvement in alveolar structure, lower inflammation | Strong inflammation reduction, improved airflow |
| Human Safet |